China antitrust enforcement became more active and broader in scope in 2017. For companies in industrial, technology, healthcare and other sectors, the year’s developments offered a practical reminder: competition-law exposure in China extends beyond merger reviews to pricing, supply arrangements, information handling and non-price conduct. The approaches taken by Chinese regulators also did not always align with those of U.S. and European authorities.
The Anti-Monopoly Law (AML) reached its tenth anniversary in 2018. In the preceding year, the agencies responsible for merger review, price-related conduct and other antitrust matters increased activity across a wider range of industries. The record suggests that companies should assess China-specific risks early, rather than assume that clearance or compliance outcomes elsewhere will determine the result.
China antitrust enforcement: a broader agency focus
The Ministry of Commerce (MOFCOM), then responsible for merger control, received 400 notifications in 2017, a 5.8% increase from 2016. It imposed conditions on seven transactions, compared with two the previous year, while blocking none. Manufacturing represented more than half of the cases reviewed, and non-simple cases accounted for 30% of the total.
MOFCOM also reported faster processing. Average acceptance and closing times declined compared with 2016, and nearly all transactions classified as simple cases were completed within the 30-day preliminary examination period. These process improvements did not eliminate substantive uncertainty: the remedies in several cases showed that the agency could require measures extending beyond the structural divestitures often emphasized in Western merger enforcement.
Merger remedies may differ across jurisdictions
The conditions imposed in 2017 varied by transaction, but several illustrate the range of measures companies may need to consider when a deal affects China.
- Divestitures and supply commitments: In Dow/DuPont, MOFCOM required divestitures related to specified pesticide and herbicide assets, as well as Dow’s acid copolymer and ionomer businesses. It also required five-year commitments on supply, pricing and distributor arrangements for certain products.
- Interoperability and information safeguards: In Broadcom/Brocade, MOFCOM required measures addressing interoperability between products, protection of third-party confidential information, and terms of sale in China. The conditions were set for ten years.
- Customer-facing commitments: In HP/Samsung, remedies included commitments concerning continued supply, reasonable prices, interoperability and future related acquisitions. U.S. and European authorities cleared that transaction without conditions.
- Capacity and operating restrictions: In Maersk Line/Hamburg Süd, MOFCOM required changes to certain vessel-sharing arrangements and a limit on capacity for a specified period. The European Commission also required changes to vessel-sharing arrangements, but the remedies were not identical.
- Hold-separate and divestiture measures: In ASE/SPIL, MOFCOM required a hold-separate arrangement and other behavioral measures for 24 months. In BD/Bard, it required divestiture of a core needle biopsy devices business, including related R&D assets.
These cases show why a global remedy package should not be assumed to satisfy every authority. MOFCOM sometimes coordinated with regulators in other jurisdictions, yet it could impose additional or different conditions, including price and supply commitments. In some matters, U.S. or European agencies imposed no conditions, while China did.
Price-related investigations reached more industries
The National Development and Reform Commission (NDRC), which handled price-related antitrust matters, continued enforcement in the medical sector and expanded attention to power, chemicals, coal and shipping. Its actions included penalties involving excessive prices and refusals to supply medical-use isoniazid ingredients, as well as a price-fixing case involving power firms in Shanxi Province. The latter resulted in penalties for an industry association and 23 participating firms.
The NDRC also acted against members of an alleged cartel involving polyvinyl chloride products, began inspections related to coal pricing, and reported anticompetitive conduct concerns in shipping. The cases underline the importance of reviewing pricing decisions and competitor interactions in their local context. A price increase or supply restriction that attracts regulatory attention may also be examined alongside market conditions, distribution arrangements and communications between competitors.
Policy changes were relevant as well. NDRC guidance addressed price regulation in monopolistic industries and government pricing practices. Rules effective January 1, 2018, narrowed government price-setting primarily to specified public utilities, nonprofit services and goods or services characterized by natural monopoly, while emphasizing a greater role for market forces.
Reporting and non-price compliance remain important
MOFCOM penalized parties in nine transactions for failing to meet AML reporting obligations, up from six in 2016. Fines ranged from RMB150,000 to RMB300,000 in the cases described. The agency generally imposed larger fines where it found intentional disregard and smaller ones where parties cooperated or took remedial steps. Although MOFCOM had authority to unwind an unreported transaction, it had not used that power.
Enforcement was not limited to merger control or pricing. The State Administration for Industry and Commerce continued an investigation into Microsoft’s sales and marketing practices, launched 18 new antitrust investigations and closed five. Local administrations also pursued matters, including in energy and construction. Companies therefore needed to consider non-price conduct and trade association participation as part of their competition compliance programs.
Practical implications for companies operating in China
The 2017 enforcement record points to several practical priorities for companies and deal teams:
- Assess whether a transaction requires an AML filing and build China review timing into deal planning.
- Evaluate potential remedies separately for China, including supply, pricing, interoperability, information-firewall and operational commitments.
- Review pricing, distribution and supply practices for competition risks, particularly where market concentration or limited alternatives may be relevant.
- Train employees on competitor communications, confidential information and trade association conduct.
- Respond promptly and cooperatively to regulator inquiries and reporting obligations.
China’s 2017 record combined faster merger-review processes with more conditional clearances and investigations across additional industries. For industrial companies and other businesses with China exposure, the central lesson is to treat antitrust planning as a local, cross-functional responsibility. Merger filings, pricing controls, commercial practices and employee guidance all warrant attention, because remedies and enforcement priorities may differ from those applied in other jurisdictions.